NASDAQ : NCNA
NuCana plc — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 1.04 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 4.35M |
| Enterprise Value | -20.63M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 4.31M |
| Shares Change (YoY) | +1,367.87% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 2.59% |
| Float | 4.31M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.16 |
| P/TBV Ratio | 0.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.73 |
| Quick Ratio | 4.56 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -730.59 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -70.26% |
| Return on Assets (ROA) | -43.49% |
| Return on Invested Capital (ROIC) | -64.16% |
| Return on Capital Employed (ROCE) | -69.73% |
| Weighted Average Cost of Capital (WACC) | 14.49% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.63M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.31 |
| 52-Week Price Change | -74.43% |
| 50-Day Moving Average | 1.24 |
| 200-Day Moving Average | 1.75 |
| Relative Strength Index (RSI) | 40.37 |
| Average Volume (20 Days) | 38,634 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 145,031 |
| Short Previous Month | 99,936 |
| Short % of Shares Out | 3.48% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.64 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -19.39M |
| Pretax Income | -14.52M |
| Net Income | -12.88M |
| EBITDA | -19.11M |
| EBIT | -19.39M |
| Earnings Per Share (EPS) | -$3.17 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 25.88M |
| Total Debt | 891,601 |
| Net Cash | 24.98M |
| Net Cash Per Share | $5.80 |
| Equity (Book Value) | 26.88M |
| Book Value Per Share | 6.24 |
| Working Capital | 23.88M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -6.85M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 283,860 |
| Net Borrowing | -53,558 |
| Free Cash Flow | -6.85M |
| FCF Per Share | -$1.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,367.87% |
| Shareholder Yield | -1,367.87% |
| Earnings Yield | -313.78% |
| FCF Yield | -157.41% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 11, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:200 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |